Tenaya Therapeutics (TNYA) EBT Margin (2026)
Tenaya Therapeutics (TNYA) posted EBT Margin of 3909.28% for Q2 2026, up 54.36% on a QoQ basis from 8565.33% in Q1 2026.
Powered by 
Analysis
Tenaya Therapeutics (TNYA) EBT Margin (2026) Analysis & Trends
Tenaya Therapeutics has reported EBT Margin for 1 years, with the latest figure at 3909.28% in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.22 Bn | 9.37 Bn | 112.79 Mn | 55.43% |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | -885.91% |
| 3 | Iovance Biotherapeutics | 3.66 Bn | 3.36 Bn | 55.72 Mn | -49.02% |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn | 14.32% |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | -1,356.24% |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | -24,299.18% |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | -0.44% |
| 9 | Vericel | 1.95 Bn | 1.78 Bn | 56.40 Mn | 2.88% |
| 10 | Tenaya Therapeutics | 140.55 Mn | 140.55 Mn | - | -3,909.28% |